The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This certification paves the way for CORONA's entry into five EAEU member nations- Russia, Kyrgyzstan, Armenia, Belarus, and Kazakhstan-under a B2B business model
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
This marks the second indication for which gumokimab has gained NDA review acceptance
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited
The collaboration will focus on enhancing surgeon capabilities, developing structured training pathways, and promoting the adoption of robotic-assisted surgery in both routine and complex procedures
The move follows AstraZeneca’s previously announced plan to complete a direct listing of its Ordinary Shares and debt securities on the New York Stock Exchange
Tatva Chintan Pharma Chem has reported total income of Rs. 133.06 crore during the period ended December 31, 2025
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
The new investment will fuel expansion of Avalon's Diagnostic Intelligence capabilities
Subscribe To Our Newsletter & Stay Updated
